$Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema$
Código QR

Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema

Tommi Karttunen,1 Lasse Nummelin,2 Kai Kaarniranta,1,2 Kati Kinnunen1,2 1Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland; 2Department of Ophthalmology, University of Eastern Finland, Kuopio, FinlandCorrespondence: Tommi KarttunenDepartment of Ophthalmology, Kuopio University...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karttunen T, Nummelin L, Kaarniranta K, Kinnunen K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	diabetic macular oedema (dmo) dexamethasone implant hyper reflective spots (hrs) optical coherence tomography (oct) Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/2601acc6ba564e71ba4fc07d9397406c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2601acc6ba564e71ba4fc07d9397406c
record_format	dspace
spelling	oai:doaj.org-article:2601acc6ba564e71ba4fc07d9397406c2021-12-02T05:20:48ZReal Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema1177-5483https://doaj.org/article/2601acc6ba564e71ba4fc07d9397406c2019-12-01T00:00:00Zhttps://www.dovepress.com/real-life-experience-of-dexamethasone-implant-in-refractory-diabetic-m-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Tommi Karttunen,1 Lasse Nummelin,2 Kai Kaarniranta,1,2 Kati Kinnunen1,2 1Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland; 2Department of Ophthalmology, University of Eastern Finland, Kuopio, FinlandCorrespondence: Tommi KarttunenDepartment of Ophthalmology, Kuopio University Hospital, Puijonlaaksontie 2, Kuopio 70210, FinlandTel +358 44 717 9582Email tommi.karttunen@kuh.fiPurpose: The purpose of this retrospective study was to examine the efficacy of dexamethasone implant in refractory diabetic macular oedema (DMO) in real life settings.Methods: In all, 24 eyes of 22 patients that required treatment with single or multiple intravitreal dexamethasone implants for refractory DMO were included in the study. Patients having macular oedema for another retinal disease were excluded from the study. The patient data were collected and analyzed retrospectively. As a demographic data age, gender, the type of diabetes and the duration of DMO were collected. Changes in central foveal thickness and the number of hyper reflective spots (HRS) were analyzed with Heidelberg SD-OCT. Furthermore, the best-corrected visual acuity (BCVA) and changes in the intraocular pressure (IOP) were measured.Results: In all, 50.0% of the eyes with baseline BCVA 0.45 (±2.4) lines in ETDRS LogMAR scale received only one implant during the follow-up of 332 (±79) days. At the end of the follow-up, BCVA was 0.26 (±2.0) lines. The other 50.0% of the eyes with baseline BCVA 0.64 (±3.0) lines received the second implant in 156 (±38) days. Central retinal thickness (CRT) at baseline was 333 (±44) μm in the eyes with only one implant and 497 (±125) μm in the eyes with 2 or more implants. IOP lowering medication was needed for 8.3% of the eyes. The decrease in the number of HRS was significant (8±17, p=0.048) in response to dexamethasone implantation.Conclusion: The dexamethasone implant is a useful treatment in refractory DMO and HRS seen in the OCT might indicate inflammation in the retina.Keywords: diabetic macular oedema, DMO, dexamethasone implant, hyper reflective spots, HRS, optical coherence tomography, OCTKarttunen TNummelin LKaarniranta KKinnunen KDove Medical Pressarticlediabetic macular oedema (dmo)dexamethasone implanthyper reflective spots (hrs)optical coherence tomography (oct)OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 2583-2590 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetic macular oedema (dmo) dexamethasone implant hyper reflective spots (hrs) optical coherence tomography (oct) Ophthalmology RE1-994
spellingShingle	diabetic macular oedema (dmo) dexamethasone implant hyper reflective spots (hrs) optical coherence tomography (oct) Ophthalmology RE1-994 Karttunen T Nummelin L Kaarniranta K Kinnunen K Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
description	Tommi Karttunen,1 Lasse Nummelin,2 Kai Kaarniranta,1,2 Kati Kinnunen1,2 1Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland; 2Department of Ophthalmology, University of Eastern Finland, Kuopio, FinlandCorrespondence: Tommi KarttunenDepartment of Ophthalmology, Kuopio University Hospital, Puijonlaaksontie 2, Kuopio 70210, FinlandTel +358 44 717 9582Email tommi.karttunen@kuh.fiPurpose: The purpose of this retrospective study was to examine the efficacy of dexamethasone implant in refractory diabetic macular oedema (DMO) in real life settings.Methods: In all, 24 eyes of 22 patients that required treatment with single or multiple intravitreal dexamethasone implants for refractory DMO were included in the study. Patients having macular oedema for another retinal disease were excluded from the study. The patient data were collected and analyzed retrospectively. As a demographic data age, gender, the type of diabetes and the duration of DMO were collected. Changes in central foveal thickness and the number of hyper reflective spots (HRS) were analyzed with Heidelberg SD-OCT. Furthermore, the best-corrected visual acuity (BCVA) and changes in the intraocular pressure (IOP) were measured.Results: In all, 50.0% of the eyes with baseline BCVA 0.45 (±2.4) lines in ETDRS LogMAR scale received only one implant during the follow-up of 332 (±79) days. At the end of the follow-up, BCVA was 0.26 (±2.0) lines. The other 50.0% of the eyes with baseline BCVA 0.64 (±3.0) lines received the second implant in 156 (±38) days. Central retinal thickness (CRT) at baseline was 333 (±44) μm in the eyes with only one implant and 497 (±125) μm in the eyes with 2 or more implants. IOP lowering medication was needed for 8.3% of the eyes. The decrease in the number of HRS was significant (8±17, p=0.048) in response to dexamethasone implantation.Conclusion: The dexamethasone implant is a useful treatment in refractory DMO and HRS seen in the OCT might indicate inflammation in the retina.Keywords: diabetic macular oedema, DMO, dexamethasone implant, hyper reflective spots, HRS, optical coherence tomography, OCT
format	article
author	Karttunen T Nummelin L Kaarniranta K Kinnunen K
author_facet	Karttunen T Nummelin L Kaarniranta K Kinnunen K
author_sort	Karttunen T
title	Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
title_short	Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
title_full	Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
title_fullStr	Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
title_full_unstemmed	Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
title_sort	real life experience of dexamethasone implant in refractory diabetic macular oedema
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/2601acc6ba564e71ba4fc07d9397406c
work_keys_str_mv	AT karttunent reallifeexperienceofdexamethasoneimplantinrefractorydiabeticmacularoedema AT nummelinl reallifeexperienceofdexamethasoneimplantinrefractorydiabeticmacularoedema AT kaarnirantak reallifeexperienceofdexamethasoneimplantinrefractorydiabeticmacularoedema AT kinnunenk reallifeexperienceofdexamethasoneimplantinrefractorydiabeticmacularoedema
_version_	1718400399157755904

Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema

Ejemplares similares